Lack of Reinfection in Rhesus Macaques Infected with SARS-CoV-2

A global pandemic of Corona Virus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is ongoing spread. It remains unclear whether the convalescing patients have a risk of reinfection. Rhesus macaques were rechallenged with SARS-CoV-2 during an early recovery phase from initial infection characterized by weight loss, interstitial pneumonia and systemic viral dissemination mainly in respiratory and gastrointestinal tracts. The monkeys rechallenged with the identical SARS-CoV-2 strain have failed to produce detectable viral dissemination, clinical manifestations and histopathological changes. A notably enhanced neutralizing antibody response might contribute the protection of rhesus macaques from the reinfection by SARS-CoV-2. Our results indicated that primary SARS-CoV-2 infection protects from subsequent reinfection. One Sentence Summary Neutralizing antibodies against SARS-CoV-2 might protect rhesus macaques which have undergone an initial infection from reinfection during early recovery days.

[1]  T. Kuiken,et al.  Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model , 2020, Science.

[2]  Xiaozhong Peng,et al.  Comparison of SARS-CoV-2 Infections Among Three Species of Non-Human Primates , 2020, SSRN Electronic Journal.

[3]  S. Anzick,et al.  Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2 , 2020, Nature.

[4]  Xiaozhong Peng,et al.  Comparison of SARS-CoV-2 infections among 3 species of non-human primates , 2020, bioRxiv.

[5]  Yang Liu,et al.  Clinical characteristics of the recovered COVID-19 patients with re-detectable positive RNA test , 2020, medRxiv.

[6]  Y. Wen,et al.  Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications , 2020, medRxiv.

[7]  O. Tsang,et al.  Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study , 2020, The Lancet Infectious Diseases.

[8]  E. Fischer,et al.  Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2 , 2020, bioRxiv.

[9]  Y. Yazdanpanah,et al.  SARS-CoV-2 specific antibody responses in COVID-19 patients , 2020, medRxiv.

[10]  H. G. Liu,et al.  [Cause analysis and treatment strategies of "recurrence" with novel coronavirus pneumonia (covid-19) patients after discharge from hospital]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[11]  Wenling Wang,et al.  Age‐related rhesus macaque models of COVID‐19 , 2020, Animal models and experimental medicine.

[12]  Wenling Wang,et al.  The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice , 2020, Nature.

[13]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[14]  J. Routy,et al.  Clinical outcome after lipectomy in the management of patients with human immunodeficiency virus-associated dorsocervical fat accumulation , 2019, Medicine.

[15]  Fu-Tong Liu,et al.  Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins , 2014, Biochemical and Biophysical Research Communications.